Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo And Ranbaxy To Launch Hypertension Drug Olmesartan In India

This article was originally published in PharmAsia News

Executive Summary

Japanese drug maker Daiichi Sankyo announced March 31 the launch of hypertension treatment Olmetec (olmesartan) in India through Indian subsidiary Ranbaxy Laboratories. Olmetec is Daiichi's best-selling drug and the company aims to utilize Ranbaxy's extensive sales force and know-how in India. Ranbaxy will market it as Olvance starting in April. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts